Resources
7 Results (showing 1 - 7)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 2/4/2020 (updated 3/28/2024)
How States are Responding to the Opioid Crisis: An Overview Webinar Presentation and Materials
Posted 4/27/2020 (updated 3/28/2024)
Communication with Stakeholders webinar that took place on April 21, 2020.
Posted 5/27/2020 (updated 3/28/2024)
Materials from the Strategies for Engaging Your Community During the Pandemic webinar held on May 19, 2020 are below.
Posted 10/21/2020 (updated 3/29/2024)
This webinar described the unique role of peer support specialists in the CDC-funded pilot project Reducing Overdose After Release from Incarceration (ROAR). The ROAR pilot combines provision of medication for opioid use disorder with support from Oregon Certified Recovery Mentors (CRMs) to reduce overdose risk among women released from prison.
Posted 5/5/2021 (updated 4/10/2024)
We discussed the importance of engaging community influencers in your efforts to improve prevention, treatment, and recovery systems and services. We talked about how to identify and engage these key community stakeholders and why this strategic activity is vital to your consortium’s sustainability.
Posted 1/24/2023 (updated 3/27/2024)
This webinar will introduce the newest RCORP program cohorts to the RCOEs, Fletcher Group, University of Rochester, and University of Vermont. These three cooperative agreements are charged with supporting the identification, translation, dissemination, and implementation of evidence-based programs and best practices, in addition to providing specialized TA to RCORP recipients and other rural providers.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.